HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ambrisentan (Myogen).

Abstract
Ambrisentan (LU-208075, BSF-208075) and LU-302146 (BSF-302146) are being developed by Myogen, under license from Abbott (formerly BASF Pharma), for the potential treatment of post-ischemic acute renal failure and cardiovascular disease . By August 2001, ambrisentan had entered phase II trials for chronic heart failure, hypertension, kidney failure and pulmonary hypertension.
AuthorsGeorge E Billman
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 3 Issue 10 Pg. 1483-6 (Oct 2002) ISSN: 1472-4472 [Print] England
PMID12431023 (Publication Type: Journal Article, Review)
Chemical References
  • Antihypertensive Agents
  • Endothelin Receptor Antagonists
  • Phenylpropionates
  • Pyridazines
  • Receptor, Endothelin A
  • ambrisentan
Topics
  • Animals
  • Antihypertensive Agents (pharmacology)
  • Drug Design
  • Endothelin Receptor Antagonists
  • Humans
  • Phenylpropionates (chemical synthesis, pharmacology)
  • Pyridazines
  • Receptor, Endothelin A
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: